Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy.

Cancer

Oh WK.
PMID: 10898346
Cancer. 2000 Jun 15;88(12):3015-21. doi: 10.1002/1097-0142(20000615)88:12+<3015::aid-cncr18>3.0.co;2-m.

BACKGROUND: Prostate carcinoma is the second leading cause of cancer-related death in men in the United States. In nearly all of these men, cancer progressed despite initial treatment with androgen ablation therapy. Managing hormone-refractory prostate carcinoma remains a difficult...

Nanoparticles for Targeting of Prostate Cancer.

Current pharmaceutical design

Yari H, Gali H, Awasthi V.
PMID: 32693761
Curr Pharm Des. 2020;26(42):5393-5413. doi: 10.2174/1381612826666200721001500.

Prostate cancer (PCa) is the leading cause of death by cancer in men. Because of the drastic decline in the survival rate of PCa patients with advanced/metastatic disease, early diagnosis of disease and therapy without toxic side effects is...

[Comprehensive nursing intervention helps improve medication compliance of prostate cancer patients undergoing endocrine therapy].

Zhonghua nan ke xue = National journal of andrology

Ding Y, Lu YW.
PMID: 32216230
Zhonghua Nan Ke Xue. 2019 May;25(5):434-436.

OBJECTIVE: To explore the role of comprehensive nursing intervention in improving medication compliance of prostate cancer patients undergoing endocrine therapy.METHODS: We practiced comprehensive nursing intervention in 43 prostate cancer patients undergoing endocrine therapy in our hospital from January 2016...

Small steps that lead to a giant leap for prostate cancer patients.

Oncology (Williston Park, N.Y.)

Crawford ED.
PMID: 25140622
Oncology (Williston Park). 2014 Aug;28(8):652.

No abstract available.

[Controversial opinions in the prostate cancer treatment].

Casopis lekaru ceskych

Pacík D.
PMID: 18020010
Cas Lek Cesk. 2007;146(10):771-5.

Attitude to prostate cancer topics has developed during last several decades explosively. Vast amount of information also brings flood of controversial opinions. Development in spiral upwards could only result from discussion based on evidence. We have not yet been...

[A history and current state of chemotherapy against prostate cancer].

Nihon rinsho. Japanese journal of clinical medicine

Yasumoto H, Igawa M.
PMID: 22208036
Nihon Rinsho. 2011 Jun;69:516-21.

No abstract available.

Nanomedicine and its applications to the treatment of prostate cancer.

Annales pharmaceutiques francaises

Ouvinha de Oliveira R, de Santa Maria LC, Barratt G.
PMID: 25220226
Ann Pharm Fr. 2014 Sep;72(5):303-16. doi: 10.1016/j.pharma.2014.04.006. Epub 2014 Jun 02.

In recent years, nanotechnology has been the focus of considerable attention in medicine due to the facility with which nanostructures interact with the body at the molecular scale. New therapies in cancer research using nanomedicine are being developed in...

[Pharmacologic treatment, tolerance and quality of life. Data of the observational UroLink study].

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica

Pala C, Spano G, Bercovich E.
PMID: 9477626
Arch Ital Urol Androl. 1997;69(5):31-2.

No abstract available.

[Pharmacologic treatment, tolerance and quality of life. Update].

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica

Bercovich E.
PMID: 9477627
Arch Ital Urol Androl. 1997;69(5):33-4.

No abstract available.

[Treatment of prostatic cancer].

Nihon Hinyokika Gakkai zasshi. The japanese journal of urology

[No authors listed]
PMID: 5893473
Nihon Hinyokika Gakkai Zasshi. 1965 Sep;56(9):963-7.

No abstract available.

Bibliography. Current world literature. Prostate cancer.

Current opinion in urology

[No authors listed]
PMID: 15069311
Curr Opin Urol. 2004 May;14(3):195-206.

No abstract available.

New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?.

Cells

Aurilio G, Cimadamore A, Santoni M, Nolè F, Scarpelli M, Massari F, Lopez-Beltran A, Cheng L, Montironi R.
PMID: 32580469
Cells. 2020 Jun 22;9(6). doi: 10.3390/cells9061522.

Medical treatment for metastatic castration-resistant prostate cancer (mCRPC) patients has progressively been evolving from a nonspecific clinical approach to genomics-oriented therapies. The scientific community is in fact increasingly focusing on developing DNA damage repair (DDR) defect-driven novel molecules, both...

Showing 1 to 12 of 14 entries